Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches

References

• O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2011;9:22–31.
   PubMedGoogle Scholar
• Messmer BT, Messmer D, Allen SL, . In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755–764.
   PubMed Web of Science ®Google Scholar
• van Gent R, Kater AP, Otto SA, . In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res 2008;68:10137–10144.
   PubMed Web of Science ®Google Scholar
• Binet JL, Caligaris-Cappio F, Catovsky D, . Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859–861.
   PubMed Web of Science ®Google Scholar
• Ghia P, Ferreri AM, Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007;64:234–246.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052–1057.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Delgado J, Pratt G, Phillips N, . Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol 2009;145:801–805.
   PubMed Web of Science ®Google Scholar
• Brezinschek HP, Foster SJ, Dorner T, . Pairing of variable heavy and variable kappa chains in individual naive and memory B cells. J Immunol 1998;160:4762–4767.
   Google Scholar
• Fais F, Ghiotto F, Hashimoto S, . Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515–1525.
   PubMed Web of Science ®Google Scholar
• Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994;15:288–294.
   PubMedGoogle Scholar
• Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5:251–262.
   PubMed Web of Science ®Google Scholar
• Messmer BT, Albesiano E, Efremov DG, . Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200:519–525.
   PubMed Web of Science ®Google Scholar
• Chu CC, Catera R, Hatzi K, . Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008;112:5122–5129.
   PubMed Web of Science ®Google Scholar
• Chu CC, Catera R, Zhang L, . Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010;115:3907–3915.
   PubMed Web of Science ®Google Scholar
• Lanemo Myhrinder A, Hellqvist E, Sidorova E, . A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008;111:3838–3848.
   PubMed Web of Science ®Google Scholar
• Catera R, Silverman GJ, Hatzi K, . Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008;14:665–674.
   PubMed Web of Science ®Google Scholar
• Capasso M, Bhamrah MK, Henley T, . HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol 2010;11:265–272.
   PubMed Web of Science ®Google Scholar
• Landgren O, Gridley G, Check D, . Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol 2007;139:791–798.
   PubMed Web of Science ®Google Scholar
• Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol 2009;147:444–449.
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Belessi C, Moreno C, . Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007;109:259–270.
   PubMed Web of Science ®Google Scholar
• Buhler A, Zenz T, Stilgenbauer S. Immunoglobulin heavy chain variable gene usage and (super)-antigen drive in chronic lymphocytic leukemia. Clin Cancer Res 2010;16:373–375.
   PubMed Web of Science ®Google Scholar
• Suljagic M, Longo PG, Bennardo S, . The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010;116:4894–4905.
   PubMed Web of Science ®Google Scholar
• Bomben R, Dal-Bo M, Benedetti D, . Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Clin Cancer Res 2010;16:620–628.
   PubMed Web of Science ®Google Scholar
• Cyster JG. B cell follicles and antigen encounters of the third kind. Nat Immunol 2010;11:989–996.
   PubMed Web of Science ®Google Scholar
• Vinuesa CG, Linterman MA, Goodnow CC, . T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 2010;237:72–89.
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL, . ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893–901.
   PubMed Web of Science ®Google Scholar
• Dal-Bo M, Bertoni F, Forconi F, . Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med 2009;7:76.
   PubMed Web of Science ®Google Scholar
• Coscia M, Pantaleoni F, Riganti C, . IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 2011;25:828–837.
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA, . Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625–1638.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, . Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639–1647.
   PubMed Web of Science ®Google Scholar
• Albesiano E, Messmer BT, Damle RN, . Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood 2003;102:3333–3339.
   PubMed Web of Science ®Google Scholar
• Willenbrock K, Jungnickel B, Hansmann ML, . Human splenic marginal zone B cells lack expression of activation-induced cytidine deaminase. Eur J Immunol 2005;35:3002–3007.
   PubMed Web of Science ®Google Scholar
• Sarsotti E, Marugan I, Benet I, . Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia. Leukemia 2004;18:743–746.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ohta H, Takemori T. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 2001;14:181–192.
   PubMed Web of Science ®Google Scholar
• Weston-Bell N, Townsend M, Di Genova G, . Defining origins of malignant B cells: a new circulating normal human IgM(+)D(+) B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population. Leukemia 2009;23:2075–2080.
   PubMed Web of Science ®Google Scholar
• Seifert M, Kuppers R. Molecular footprints of a germinal center derivation of human IgM + (IgD +)CD27 + B cells and the dynamics of memory B cell generation. J Exp Med 2009;206:2659–2669.
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata JM, Andreeff M, . Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;106:995–1004.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, . Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655–2663.
   PubMed Web of Science ®Google Scholar
• Willimott S, Baou M, Huf S, . Separate cell culture conditions to promote proliferation or quiescent cell survival in chronic lymphocytic leukemia. Leuk Lymphoma 2007;48:1647–1650.
   PubMed Web of Science ®Google Scholar
• Lanham S, Hamblin T, Oscier D, . Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101: 1087–1093.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007;20:399–413.
   PubMed Web of Science ®Google Scholar
• Dameshek W. Chronic lymphocytic leukemia—an accumulative disease of immunolgically incompetent lymphocytes. Blood 1967; 29(Suppl.):566–584.
   PubMedGoogle Scholar
• Keating MJ, Chiorazzi N, Messmer B, . Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2003:153–175.
   PubMedGoogle Scholar
• Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008;264:549–562.
   PubMed Web of Science ®Google Scholar
• Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519–2526.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Balakrishnan K, Chen R, . Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114:4441–4450.
   PubMed Web of Science ®Google Scholar
• Ghia P, Granziero L, Chilosi M, . Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol 2002;12: 149–155.
   PubMed Web of Science ®Google Scholar
• Granziero L, Ghia P, Circosta P, . Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777–2783.
   PubMed Web of Science ®Google Scholar
• Smit LA, Hallaert DY, Spijker R, . Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007;109:1660–1668.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perez-Galan P, Liu D, . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563–574.
   PubMed Web of Science ®Google Scholar
• Vandewoestyne ML, Pede VC, Lambein KY, . Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles. Leukemia 2011;25:883–888.
   PubMed Web of Science ®Google Scholar
• Bagnara D, Kaufman MS, Calissano C, . A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011;117:5463–5472.
   PubMed Web of Science ®Google Scholar
• Hamilton D, Cowan RA, Sharma HL, . The behaviour of autologous indium-114m-labelled lymphocytes in patients with lymphoid cell malignancy. J Nucl Med 1988;29:485–493.
   PubMed Web of Science ®Google Scholar
• Wagstaff J, Gibson C, Thatcher N, . The migratory properties of indium-111 oxine labelled lymphocytes in patients with chronic lymphocytic leukemia. Br J Haematol 1981;49:283–291.
   PubMed Web of Science ®Google Scholar
• Jurlander J. The cellular biology of B-cell chronic lymphocytic leukemia. Crit Rev Oncol Hematol 1998;27:29–52.
   PubMed Web of Science ®Google Scholar
• Nilsson J, Soderberg O, Nilsson K, . Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells. Blood 2000;95:1420–1426.
   PubMed Web of Science ®Google Scholar
• Backman E, Bergh AC, Lagerdahl I, . Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro. Haematologica 2007;92:1495–1504.
   Google Scholar
• Schmid C, Isaacson PG. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994;24:445–451.
   PubMed Web of Science ®Google Scholar
• Patten PE, Buggins AG, Richards J, . CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111:5173–5181.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Aydin S, Grand MM, . CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med 2010;16:87–91.
   PubMed Web of Science ®Google Scholar
• Tonino SH, Spijker R, Luijks DM, . No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. Blood 2008;112:840–843.
   PubMed Web of Science ®Google Scholar
• Hartmann TN, Grabovsky V, Wang W, . Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res 2009;69:3121–3130.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, . In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006;108:1135–1144.
   PubMed Web of Science ®Google Scholar
• Gattei V, Bulian P, Del Principe MI, . Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008;111:865–873.
   PubMed Web of Science ®Google Scholar
• Burkle A, Niedermeier M, Schmitt-Graff A, . Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007;110:3316–3325.
   PubMed Web of Science ®Google Scholar
• Scielzo C, Ten Hacken E, Bertilaccio MT, . How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection. Leuk Lymphoma 2010;51:1371–1374.
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Burger JA, Quiroga MP, . Influence of bone marrow stromal microenvironment on forodesine-induced response in CLL primary cells. Blood 2010;116:1083–1091.
   PubMed Web of Science ®Google Scholar
• Shehata M, Schnabl S, Demirtas D, . Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the anti-apoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010;116:2513–2521.
   PubMed Web of Science ®Google Scholar
• Felten DL, Livnat S, Felten SY, . Sympathetic innervation of lymph nodes in mice. Brain Res Bull 1984;13:693–699.
   PubMed Web of Science ®Google Scholar
• Fink T, Weihe E. Multiple neuropeptides in nerves supplying mammalian lymph nodes: messenger candidates for sensory and autonomic neuroimmunomodulation? Neurosci Lett 1988;90:39–44.
   PubMed Web of Science ®Google Scholar
• Bellinger DL, Millar BA, Perez S, . Sympathetic modulation of immunity: relevance to disease. Cell Immunol 2008;252:27–56.
   PubMed Web of Science ®Google Scholar
• Bhowmick S, Singh A, Flavell RA, . The sympathetic nervous system modulates CD4(+)FoxP3(+) regulatory T cells via a TGF-beta-dependent mechanism. J Leukoc Biol 2009;86:1275–1283.
   PubMed Web of Science ®Google Scholar
• MacLennan IC. Germinal centers still hold secrets. Immunity 2005;22:656–657.
   PubMed Web of Science ®Google Scholar
• Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008;8:22–33.
   PubMed Web of Science ®Google Scholar
• Natkunam Y. The biology of the germinal center. Hematology Am Soc Hematol Educ Program 2007:210–215.
   Google Scholar
• Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994;367:425–428.
   PubMed Web of Science ®Google Scholar
• Okada T, Miller MJ, Parker I, . Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 2005;3:e150.
   PubMed Web of Science ®Google Scholar
• Grdisa M. Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro. Leuk Res 2003;27:951–956.
   PubMed Web of Science ®Google Scholar
• Bromberg JS. The beginnings of T-B collaboration. J Immunol 2004;173:7–8.
   PubMed Web of Science ®Google Scholar
• D'Arena G, Laurenti L, Minervini MM, . Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 2011;35:363–368.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Schmitt M, Kowal M, . Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008;20:677–682.
   PubMed Web of Science ®Google Scholar
• Jak M, Mous R, Remmerswaal EB, . Enhanced formation and survival of CD4 + CD25hi Foxp3 + T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788–801.
   PubMed Web of Science ®Google Scholar
• Luqman M, Klabunde S, Lin K, . The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711–720.
   PubMed Web of Science ®Google Scholar
• Burger JA, Ghia P, Rosenwald A, . The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367–3375.
   PubMed Web of Science ®Google Scholar
• Ghia P, Strola G, Granziero L, . Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4 +, CD40L + T cells by producing CCL22. Eur J Immunol 2002;32:1403–1413.
   PubMed Web of Science ®Google Scholar
• Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177:925–935.
   PubMed Web of Science ®Google Scholar
• Packham G, Stevenson F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol 2010;20:391–399.
   PubMed Web of Science ®Google Scholar
• Crawford DH, Catovsky D. In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology 1993;80:40–44.
   PubMed Web of Science ®Google Scholar
• Steele AJ, Prentice AG, Cwynarski K, . The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 2011;116:4569–4577.
   Web of Science ®Google Scholar
• Jacob A, Pound JD, Challa A, . Release of clonal block in B cell chronic lymphocytic leukaemia by engagement of co-operative epitopes on CD40. Leuk Res 1998;22:379–382.
   PubMed Web of Science ®Google Scholar
• Hayden RE, Pratt G, Drayson MT, . Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance. Haematologica 2010;95:1889–1896.
   PubMed Web of Science ®Google Scholar
• Hallaert DY, Jaspers A, van Noesel CJ, . c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008;112:5141–5149.
   PubMed Web of Science ®Google Scholar
• Willimott S, Baou M, Naresh K, . CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 2007;138:721–732.
   PubMed Web of Science ®Google Scholar
• Vogler M, Butterworth M, Majid A, . Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403–4413.
   PubMed Web of Science ®Google Scholar
• Hayden RE, Pratt G, Davies NJ, . Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia 2009;23: 292–304.
   PubMed Web of Science ®Google Scholar
• Tromp JM, Tonino SH, Elias JA, . Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010;29:5071–5082.
   PubMed Web of Science ®Google Scholar
• Hallaert DY, Spijker R, Jak M, . Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 2007;14:1958–1967.
   PubMed Web of Science ®Google Scholar
• Kater AP, Evers LM, Remmerswaal EB, . CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004;127:404–415.
   PubMed Web of Science ®Google Scholar
• Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004;45:2365–2372.
   PubMed Web of Science ®Google Scholar
• McCaig AM, Cosimo E, Leach MT, . Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol 2011 Feb 24. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Coope HJ, Atkinson PG, Huhse B, . CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002;21:5375–5385.
   PubMed Web of Science ®Google Scholar
• Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995;85:3556–3565.
   PubMed Web of Science ®Google Scholar
• Plander M, Seegers S, Ugocsai P, . Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009;23:2118–2128.
   PubMed Web of Science ®Google Scholar
• Pallasch CP, Wendtner CM. Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:498–501.
   PubMed Web of Science ®Google Scholar
• Willimott S, Merriam T, Wagner SD. Apoptosis induces Bcl-XS and cleaved Bcl-XL in chronic lymphocytic leukaemia. Biochem Biophys Res Commun 2011;405:480–485.
   PubMed Web of Science ®Google Scholar
• Veldurthy A, Patz M, Hagist S, . The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008;112:1443–1452.
   PubMed Web of Science ®Google Scholar
• Amrein L, Hernandez TA, Ferrario C, . Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 2008;143:698–706.
   PubMed Web of Science ®Google Scholar
• Amrein PC, Attar EC, Takvorian RW, . Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2977–2986.
   PubMed Web of Science ®Google Scholar
• Zauli G, Voltan R, Bosco R, . Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011;17:762–770.
   PubMed Web of Science ®Google Scholar
• Krause G, Hallek M. On the assessment of dasatinib-induced autophagy in CLL. Leuk Res 2011;35:137–138.
   PubMed Web of Science ®Google Scholar
• Serpa M, Bendit I, Seguro F, . Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia. Acta Haematol 2010;124:105–109.
   PubMed Web of Science ®Google Scholar
• Pitini VV. The role of p53 and autophagy in Dasatinib resistance of CLL lymphocytes. Leuk Res 2011;35:32–33.
   PubMed Web of Science ®Google Scholar
• Amrein L, Soulieres D, Johnston JB, . p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leuk Res 2011;35:99–102.
   PubMed Web of Science ®Google Scholar
• Harr MW, Caimi PF, McColl KS, . Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ 2010;17:1381–1391.
   PubMed Web of Science ®Google Scholar
• Song Z, Lu P, Furman RR, . Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res 2010;16:587–599.
   PubMed Web of Science ®Google Scholar
• Tavolaro S, Chiaretti S, Messina M, . Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors. Leuk Res 2010;34:733–741.
   PubMed Web of Science ®Google Scholar
• Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2008;30:543–588.
   PubMedGoogle Scholar
• Bazargan A, Tam CS. New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents. Leuk Lymphoma 2010;51:1596–1611.
   PubMed Web of Science ®Google Scholar
• Murray JA, Khanim FL, Hayden RE, . Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Br J Haematol 2010;149:65–69.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Holyoake TL. Can we afford to let sleeping dogs lie? Blood 2005;105:1840–1841.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, . Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399–404.
   PubMed Web of Science ®Google Scholar
• Moreton P, Kennedy B, Lucas G, . Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971–2979.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, . Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 2009;115:3830–3841.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, . Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343–5349.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, . Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094–1100.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. CLL microenvironment: macro important. Blood 2011;117:377–378.
   PubMed Web of Science ®Google Scholar
• Hertlein E, Triantafillou G, Sass EJ, . Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2011;116:2554–2558.
   Web of Science ®Google Scholar
• Wierda WG, Castro JE, Aguillon R, . A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 2010;24:1893–1900.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Andritsos L, Liu Q, . Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010;115:2619–2629.
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Wierda WG, Keating MJ, . Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008;112:1971–1980.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia 2005;19:2195–2202.
   PubMed Web of Science ®Google Scholar
• Leupin N, Luthi A, Novak U, . P73 status in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2004;45:1205–1207.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, . Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2011;116:2078–2088.
   Web of Science ®Google Scholar
• Scrivener S, Goddard RV, Kaminski ER, . Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383–389.
   PubMed Web of Science ®Google Scholar
• Gorgun G, Holderried TA, Zahrieh D, . Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005;115:1797–1805.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, . Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427–2437.
   PubMed Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V, . Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618–621.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yu B, Triantafillou G, . Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112:5180–5189.
   PubMed Web of Science ®Google Scholar
• Idler I, Giannopoulos K, Zenz T, . Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2010;148:948–950.
   PubMed Web of Science ®Google Scholar
• Awan FT, Johnson AJ, Lapalombella R, . Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:27–38.
   PubMed Web of Science ®Google Scholar
• Brown JR. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong? Leuk Lymphoma 2010; 51:1382–1385.
   PubMed Web of Science ®Google Scholar
• Brown JR, Abramson J, Hochberg E, . A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010;24:1972–1975.
   PubMed Web of Science ®Google Scholar
• Miller KC, Musial L, Whitworth A, . Management of patients with chronic lymphocytic leukemia treated with lenalidomide. Clin J Oncol Nurs 2010;14:491–499.
   PubMed Web of Science ®Google Scholar